Recurrent hepatic encephalopathy (HE) is a leading cause of readmission despite standard of care (SOC) associated with microbial dysbiosis. Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it has not been studied in HE. We aimed to define whether FMT using a rationally derived stool donor is safe in recurrent HE compared to SOC alone. An open-label, randomized clinical trial with a 5-month follow-up in outpatient men with cirrhosis with recurrent HE on SOC was conducted with 1:1 randomization. FMT-randomized patients received 5 days of broad-spectrum antibiotic pretreatment, then a single FMT enema from the same donor with the optimal microbiota deficient in HE. Follow-up occurred on days 5, 6, 12, 35, and 150 postrandomization. The primary outcome was safety of FMT compared to SOC using FMT-related serious adverse events (SAEs). Secondary outcomes were adverse events, cognition, microbiota, and metabolomic changes. Participants in both arms were similar on all baseline criteria and were followed until study end. FMT with antibiotic pretreatment was well tolerated. Eight (80%) SOC participants had a total of 11 SAEs compared to 2 (20%) FMT participants with SAEs (both FMT unrelated; P 5 0.02). Five SOC and no FMT participants developed further HE (P 5 0.03). Cognition improved in the FMT, but not the SOC, group. Model for End-Stage Liver Disease (MELD) score transiently worsened postantibiotics, but reverted to baseline post-FMT. Postantibiotics, beneficial taxa, and microbial diversity reduction occurred with Proteobacteria expansion. However, FMT increased diversity and beneficial taxa. SOC microbiota and MELD score remained similar throughout. Conclusion: FMT from a rationally selected donor reduced hospitalizations, improved cognition, and dysbiosis in cirrhosis with recurrent HE.
often ineffective and recurrent HE can result in cumulative, irreversible brain injury. (6) (7) (8) HE patients have a reduced relative abundance of beneficial short-chain fatty acid (SCFA) producing families, such as Lachnospiraceae and Ruminococcaceae, and enrichment of potentially pathogenic Enterobacteriaceae. (9) (10) (11) (12) (13) This microbial profile has been linked to cognitive impairment and systemic inflammation, which can predict negative outcomes. (14, 15) Accordingly, microbiomedirected therapy that can complement microbial deficiencies may reduce HE recurrence.
Fecal microbiota transplants (FMTs) have been shown, in randomized controlled trials, to be effective in dysbiotic conditions such as recurrent Clostridium difficile and ulcerative colitis. (16) (17) (18) (19) Cross-sectional data demonstrating microbial dysbiosis in HE (20) and a case report (21) suggest that FMT may be promising. However, given data suggesting heterogeneity in stool donor efficacy in ulcerative colitis, (18) we chose to use a single rationally identified donor for complementing the unique deficiencies among HE patients. The aim of our open-label, randomized clinical trial was to assess the safety, impact on liver, and cognitive function of patients undergoing FMT using a rationally derived donor in recurrent HE.
Patients and Methods

RATIONAL DONOR SELECTION
Using microbiome data from HE and healthy control participants, we performed a machine learning technique to identify a single donor who had the highest relative abundances of Lachnospiraceae and Ruminococcaceae among a universal stool donor bank (Supporting Information). All donor material came from a single stool specimen provided by this donor for all FMT-assigned patients.
STUDY DESIGN
This was an open-label, randomized clinical trial among patients with cirrhosis with recurrent HE on SOC comparing FMT preceded by antibiotic pretreatment (FMT arm) versus SOC alone (SOC arm). This trial was carried out under U.S. Food and Drug Administration (FDA) Investigational New Drug 16542 at the McGuire Veterans Administration Medical Center (VAMC) and approved by the institutional review board. The trial is registered at www.clinicaltrials.gov (NCT02636647). All participants provided informed consent, and an independent data safety monitoring board (DSMB) evaluated the trial on an ongoing basis. Participants underwent screening procedures including complete blood count, Model for End-Stage Liver Disease (MELD) calculation, (22) stool analysis for Clostridium difficile and a 24-hour dietary recall. If eligible, participants were randomized 1:1 using a random number generator into the FMT or SOC arm. Participants were evaluated at days 0, 5, 6, 12, 20, and 35 and 150 postrandomization for a safety assessment (Fig. 1A) . All subjects were instructed to maintain their regular Western diet during the trial, which was confirmed at each visit.
STUDY POPULATION
Twenty eligible patients were aged 18 years outpatients with cirrhosis with recurrent HE defined as at least two documented overt HE episodes requiring therapy and supervised by an adult caregiver. Patients were excluded if they had a MELD score >17, on oral or intravenous antimicrobial agents besides nonabsorbable rifaximin, allergies to pretreatment antibiotics, immunosuppressive medications, positive C. difficile test, pregnancy, active infection, those with active alcohol abuse, and unable to provide informed consent (Supporting Table S1 ).
ARTICLE INFORMATION:
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FIG. 1.
Patient flow and study design.(A) Flow chart of study design; patients were followed for 150 days after enrollment. At day 5 after randomization (postantibiotics in the FMT arm), blood, urine, and stool were collected from all participants and AEs, new medications, and diagnoses as well as adherence to the original diet was documented. All participants were seen at day 6 after randomization (day 1 post-FMT in the FMT arm) where a solicited/unsolicited AE assessment, safety laboratories (MELD score, liver function tests, CBC), urine, and stool was collected. Similarly, at days 12 and 20 postrandomization, we performed safety laboratories, collected blood, urine, and stool, and evaluated AEs. At day 20, both cognitive tests were readministered. At day 35, we collected safety laboratories and evaluated AEs. At day 150, SAE assessment was conducted. (B) CONSORT flow chart showing that there were no dropouts and all subjects were followed throughout the study. Abbreviation: CBC, complete blood count; CONSORT, Consolidated Standards of Reporting Trials.
BASELINE ASSESSMENT
Potential participants were evaluated for demographic information, cirrhosis/HE history, medication profile, and underwent two validated neurocognitive tests, psychometric hepatic encephalopathy score (PHES), and EncephalApp-Stroop. (1, 23) PHES is a five-test battery, which yields a composite standard deviation score compared to local norms whereas the time required to complete five runs in the On and Off state by EncephalApp-Stroop (OffTime1OnTime) is recorded (Supporting Information). (23) Blood samples were drawn for hepatic panel and complete blood count. Stool was analyzed at baseline to rule out C. difficile and other enteric infections. A separate stool aliquot was collected in RNALater for 16s ribosomal RNA (rRNA) microbiome analysis. (10) Urine samples during the visit were snap-frozen for nuclear magnetic resonance (NMR) metabolomics. (24) 
INTERVENTION
Participants randomized to the FMT arm were given pretreatment antibiotics to decrease the host bacterial load, lower diversity, and enable a colonic colonization of the donor microbiota. (25) Lactulose and rifaximin were continued for all patients throughout the trial. A 5-day broad-spectrum coverage regimen was used (metronidazole 500 mg orally three times daily, ciprofloxacin 500 mg orally twice-daily, and amoxicillin 500 mg orally three times daily). All antibiotics were discontinued at least 12 hours before FMT to ensure that these agents would not impact the instilled microbiota. FMT was prepared from a healthy volunteer from a universal stool bank (OpenBiome) (Supporting Information). Three frozen-then-thawed FMT units (90 mL total) were instilled by enema and retained for 30 minutes. (26) Participants in the SOC arm did not receive antibiotic pretreatment or FMT, but follow-up was identical on days 5, 6, 12, 35, and 150 postrandomization (Fig. 1A) .
CLINICAL OUTCOMES
The primary outcome was proportion of participants with FMT-related serious adverse events (SAEs) at day 150, a composite endpoint of death, hospitalizations, emergency room visits or transmissible infections, as defined by the FDA. The secondary outcomes were changes in cognitive function at day 20, cirrhosis severity (MELD score, albumin), changes in liver function and white blood cell (WBC) count, development of all adverse events (AEs), and changes in microbiota composition and function in the FMT arm compared to SOC arm. In addition to SAEs, solicited AE events at each visit included: (1) gastrointestinal symptoms (diarrhea, abdominal pain, or bloating); (2) liver associated (HE, jaundice, or changes in liver function); (3) infections; and (4) related to enema (rectal bleeding/trauma).
ASSESSMENT AND ANALYSIS OF MICROBIOME AND METABOLOMICS
Stool was analyzed for microbiota composition using 16s rRNA sequencing using Multitag sequencing on an Ion Torrent PGM. (10) Microbiota relative abundance was analyzed using UNIFRAC, principal component analysis (PCA), and linear discriminant analysis effect size (LEFSe) between and within groups and also compared to the donor. (27, 28) The microbiota analysis was divided in the FMT groups into baseline versus postantibiotics (day 0 vs. day 5) and using post-FMT samples (day 5 vs. days [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The Shannon Diversity index was used to define diversity in groups; analysis was performed using paired Wilcoxon tests at different time points within each group and Mann-Whitney U test between groups. Urine samples were analyzed using NMR spectroscopy using published metabolomic techniques (Supporting Information). (24) 
STATISTICAL ANALYSIS
All analyses were performed using the intention-totreat principle. SAEs were compared between arms at 150 days postrandomization using Fisher's exact test. Wilcoxon's paired tests were performed within groups at each time point for MELD score, WBC count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum albumin, and hemoglobin as well as between groups at each time point using MannWhitney U tests. A similar comparison was performed between and within groups for PHES and EncephalApp-Stroop. A safety power post-hoc calculation gave a power of 83% for SAE risk between arms; for PHES the power was 84% and for EncephalApp-Stroop it was 97%. All authors had access to the study data and reviewed and approved the final manuscript.
Results
PATIENTS
Between October 2015 and July 2016, we screened 44 patients. Nine declined and 15 did not meet eligibility. Overall, 20 participants were enrolled in the trial and randomized 1:1 into the FMT or SOC arm (Fig.  1A) . All participants had similar baseline demographics, laboratory parameters, and cirrhosis severity ( Table 1 ).
AEs AND CLINICAL OUTCOMES
All subjects randomized to the FMT arm tolerated the pretreatment antibiotics and the FMT. There were no hospitalizations in the FMT arm for alteration in mental status. Among the FMT arm, 2 patients were hospitalized within 5 months; 1 at day 84 post-FMT with acute kidney injury that responded within 24 hours to intravenous hydration and 1 at day 115 because of chest pain that was ruled out for an acute cardiac event; both were judged to be unrelated to FMT by the DSMB. Eleven SAEs occurred among 8 participants (80%) in the SOC arm, including nine events linked to liver-related complications (six for alteration in mental status, one pneumonia, one for chest pain, one for portal vein thrombus, one for anemia, one for gastroenteritis, and two for variceal bleeding [one had HE1variceal bleeding and one had HE1pneumonia]), which was significantly higher than the FMT arm (20%; P 5 0.02 Table 2 and Supporting Table S2 ). The pneumonia and gastroenteritis occurred at day 89 and day 74, respectively. Specifically, the occurrence of HE was also significantly higher in the SOC group (Table 2 and Supporting Table S2 ). Of the six episodes, four of these required hospitalization for inpatient management. Four episodes were precipitated (one pneumonia, one variceal bleeding, one hyponatremia, and one constipation) whereas the remainder were spontaneous. For those with recurrent HE, because patients were already on maximal HE-related treatment in the SOC group and following prescribed diets, no changes apart from those to correct and prevent further precipitating factors were made. When the safety outcome within 35 days of enrollment was considered, there were two hospitalizations in the SOC group (1 patient with variceal bleeding and HE and the other for portal vein thrombus) and none in FMT.
None of the participants in either arm were started on antibiotics unless they developed an infection that . None of these participants had acute kidney injury or spontaneous bacterial peritonitis noted within 7 days of paracentesis as part of the SAEs. All the included patients had evidence of portosystemic shunting on abdominal imaging and varices on endoscopy, and none had transjugular intrahepatic portosystemic shunts (TIPS) in place. None of the subjects were lost to follow-up. There were no deaths or transmissible infections noted in either study arm. None of the participants reached a grade of 3 or change in >2 of any of their gastrointestinal symptoms according to a standard symptom severity chart (Supporting Table  S5 ). None of the participants developed significant changes in a priori safety laboratory parameters (WBC >12,000 or <1,000/mm 3 , MELD >8 increase, and AST or ALT >10 times upper limit of normal [ULN]), which occurred outside the SAEs described. Caloric intake and protein intake remained similar within and between groups throughout the trial (Supporting Table S6 ).
There was no significant change in MELD scores throughout the trial in the SOC arm. In the FMT arm, use of antibiotics worsened MELD score (international normalized ratio and bilirubin were similarly affected; creatinine was stable); however, FMT recovered MELD score to the baseline value (Table 2 and  Supporting Tables S3 and S4 ). No changes in WBC count, AST, ALT, albumin, or hemoglobin were observed in either arm (Table 2 and Supporting Table  S3 ). Use of lactulose and rifaximin remained consistent throughout the trial regardless of subject assignment.
COGNITIVE OUTCOMES
There was a significant improvement in PHES total score (P 5 0.003) and EncephalApp Stroop (P 5 0.01) in the FMT group compared to baseline, but none in prevalues and postvalues among the SOC arm (PHES, P 5 0.98; EncephalApp, P 5 0.26; Table 2 ; Fig. 2 ).
MICROBIOME AND METABOLOMIC OUTCOMES
At baseline, there was similar microbiota composition on weighted UNIFRAC (P 5 0.3) and Shannon diversity index (P 5 0.1, Mann-Whitney U test) between FMT and SOC groups. Postantibiotics, a significant reduction in diversity (Fig. 3C ) occurred in the FMT arm, which increased post-FMT and returned to the pre-FMT values. No change in SOC diversity indices was observed. In the SOC arm, no significant changes in microbiota composition or diversity were observed throughout the trial (all P > 0.05; Fig. 3A ,C and Supporting Fig. S3A-E) , whereas the FMT arm demonstrated significant compositional changes after antibiotics on UNIFRAC (P values, 0.01 to Mean 6 SD, unless stated otherwise. A significantly higher proportion of participants in the SOC arm experienced SAEs, and the number of hospitalizations were also the higher in this group. There was also an improvement in cognitive function in the FMT group, whereas hepatic function and blood count variables changed similarly between groups. *Mann-Whitney U test.
<1.0e-02); on PCA, loss of diversity and reduced autochthonous taxa and increased Proteobacteria relative abundance (Fig. 3B,C and Supporting Figs. S2A and S3F,G). A relative increase in beneficial taxa (Lactobacillaceae, Bifidobacteriaceae) was observed post-FMT (Supporting Figs. S2B,C and S3H-J) compared to postantibiotics and to the SOC group (Supporting Fig. S2D,E) . Compared to the donor, a significant reduction in relative abundance of Bacteroidetes and expansion of Firmicutes occurred postantibiotics which increased post-FMT. However Proteobacteria, which were low in the donor, remained similar across participants apart from the 2 FMT patients who were subsequently hospitalized (Supporting Fig. S4A ), whereas the same patients had a persistently lower Lachnospiraceaeae and Ruminococcaceae, which were the highest in the donor (Supporting Fig. S4B ). Overall, patients in the FMT arm had an increase in relative abundance of Lachnospiraceaeae and Ruminococcaceae post-FMT compared to their postantibiotic microbiome, and patients were enriched with Ruminococcaceae post-FMT compared to baseline (Supporting Fig. S4B ). Urinary metabolomics showed that the overall metabolic profile in the SOC arm remained similar over time ( Supporting Fig. S5A ). Within the FMT group, metabolites were altered by antibiotics (reduced phenylacetylglutamine [PAG; P 5 0.017], hippurate [P 5 0.04], and formate [P 5 0.007]), but returned to baseline post-FMT (Supporting Fig. S5B ; Supporting Table S7 ). When SOC and FMT groups were compared, antibiotics decreased hippurate, formate, and PAG in FMT participants, which largely returned to baseline post-FMT.
Discussion
Recurrent HE is the leading cause of readmissions in patients with cirrhosis despite SOC and may lead to irreversible neurocognitive injury. (2) HE patients have disrupted gut microbiota, partly driven by frequent antibiotic use, which results in further HE recurrence. (6) FMT is a promising therapy to restore a healthy microbiota; however, its safety profile among vulnerable HE patients that are immunosuppressed and at risk of bacteremia attributed to bacterial translocation is unknown.
In this pilot, open-label, randomized clinical trial, we deploy a novel approach by rationally selecting a stool donor based on cross-sectional HE microbiome data. Overall, the primary outcome was met with no FMT-associated SAE, including no bacterial infections. Even more striking was the reduction in hospitalizations attributed to liver-related, especially portal hypertensive, complications; in the FMT arm, recognizing a high rate of SOC hospitalizations is expected among those with end-stage liver disease.
(2) These findings were observed despite adherence to all medications, including lactulose and rifaximin, which was reinforced and inquired upon during each study visit, and both arms balanced for all clinically relevant factors at baseline.
Broad-spectrum pretreatment antibiotics were used pre-FMT to decrease the host bacterial burden and lower microbial diversity to enable a colonic environment receptive to colonization from a donor's microbiota. (17, 25, 29) This approach has been demonstrated in FMT for ulcerative colitis, where patients have a low diversity secondary to antibiotics, and clinically improve post-FMT with a corresponding increase in diversity. (30) As anticipated, there was a significant disruption of the hosts' microbial diversity with antibiotic pretreatment. However, antibiotics further reduced the already depleted autochthonous taxa (10) beyond HE patients' already dysbiotic baseline. (20, 24) The increase in MELD score transiently during antibiotic therapy is interesting and unrelated to direct drug toxicity. Depletion of gut microbial diversity, including autochthonous taxa with changes in vitamin K as well as other alterations of the gut-liver axis, could be contributory.
Accordingly, the choice to use a single donor enriched in these autochthonous taxa may have helped microbial restoration, including restoring the diversity and enhancement of beneficial taxa such as Ruminococcaceae as well as increasing Bifidobacteriaceae and Lactobacillaceae. This increase in beneficial taxa could have contributed to the overall improvement in cognitive function and, potentially, prevention of liver-related hospitalizations. (31) Strengthening of intestinal barrier by SCFA production and reducing the relative abundance of potentially pathogenic taxa could be contributory to this. (11, 12, (32) (33) (34) These taxa are indicative of a healthy microbiota and their depletion is found in several other diseases, such as nonalcoholic fatty liver and C. difficile. (35, 36) We believe that these results may be applicable to other studies in HE given that the sequences sent to map the ideal donor were different from the patients who were ultimately recruited for FMT. Therefore, the success of the trial in patients whose stool had not been evaluated a priori could increase the generalizability of these results in other HE patients and centers. These results extend previous studies in which probiotic supplementation with similar taxa improves dysbiosis and reduces hospitalizations in cirrhosis. (31, (37) (38) (39) These results are a first step for other centers to evaluate strategies that are gut based, which can potentially improve outcomes even after currently available maximal gut-based HE therapy. However, further larger trials are needed. Whereas FMT studies in C. difficile have not definitively linked clinical outcome to "donor engraftment," our use of the rationally derived donor enriched in beneficial taxa likely led to their increase in FMT patients, and these findings are not simply related to postantibiotic recovery.
The PHES and EncephalApp-Stroop are validated HE-related cognitive function tests and performance on these is associated with further HE development, hospitalizations, and death.
(1,40) Independent improvement in these tests in the FMT group is promising and suggests a clinically meaningful impact of the FMT on the gut-liver-brain axis.
(1,23) Indeed, a participant randomized to the FMT arm whose cognitive performance worsened had a high Proteobacteria relative abundance at baseline with the lowest response to the FMT and was hospitalized. Although there were not enough FMT patients with poor outcomes, we speculate that baseline Proteobacteria relative abundance could predict potential microbiota colonization and this requires further validation.
Intriguingly, from a mechanism perspective, the MELD score worsened after antibiotic pretreatment attributed to an increase in all three components. This, paralleling the microbiota, was restored post-FMT and was not accompanied by AST/ALT changes. These findings point toward a mechanism unrelated to drug-induced liver injury and could be related to autochthonous taxa depletion, which may perpetuate liver injury in models of antibiotic use. (41) Thus, either an infection or subsequent antibiotics may perpetuate liver injury in cirrhosis. Beyond microbiota changes, there were changes in functionality inferred by alterations in urinary mammalian-microbial cometabolite levels, including formate, hippurate, and PAG. (42) Previous studies have implicated an increase in formate to higher Proteobacteria taxa, hippurate to Firmicutes taxa, and PAG levels to bacterial degradation of phenylalanine. (43) The urinary metabolic profile returned toward baseline postantibiotic treatment and FMT, which supports the interpretation from the microbiome data that antibiotic-associated disruption of the gut-liver axis can be restored by FMT and may prevent further dysbiosis-associated liver injury.
Given the frequency of antibiotic use, the rate of antibiotic-resistant bacterial (ARB) infections in decompensated patients with cirrhosis is significant. (4, 5) Accordingly, the use of antibiotic pretreatment was approached with caution, and an antibiotic-only group or placebo group was not included given the primary safety aim and the objective endpoints of the study. However, a double-therapy approach with FMT was selected given preliminary evidence suggesting the protective ability of FMT to treat multiple ARBs in subjects without cirrhosis. (44, 45) Although we did not specifically assess for ARB colonization, no ARB or antibiotic-sensitive infections occurred in the FMT arm.
This study has several limitations. First, combined pretreatment antibiotics and FMT makes it difficult to discern the precise role of FMT alone. However, given the potential for ARB infections, the use of antibiotics alone as a control arm was deemed unethical. Additionally, pretreatment antibiotics were felt necessary to facilitate colonization of donor microbiota, although there is a paucity of robust clinical evidence on the degree to which it contributes to efficacy. Future studies, using FMT alone, may clarify this question. Second, the control arm was SOC, not placebo antibiotics, and sham FMT or autologous FMT. However, the primary and key secondary outcomes are objective, assessed by the independent DSMB, and unlikely to be driven by a placebo effect. Third, the dose of fecal material, dosing frequency, and ideal donor and delivery modality are unknown given that these can affect FMT efficacy in other diseases. (46, 47) Specifically, given the selected donor approach, the results may not be generalized to FMT from different donors and administration routes. (48) Fourth, the precise mechanism of FMT still requires further elucidation, but we speculate that the single donor enriched in the beneficial, autochthonous taxa could be key and the expansion of potentially probiotic taxa. Fifth, given the small sample size, further larger studies are needed to confirm this outcome in larger sample sizes and other settings, including among women and in those with MELD scores higher than 17, to refine the treatment approach. Last, we only performed cognitive and microbiota analyses to 20 days.
A longer period of cognitive and microbiota follow-up as well as patient-reported outcomes beyond AEs would have yielded greater insight into these changes post-FMT. However, regardless of the size, the treatment effect is noteworthy in this population with limited therapeutic options.
We conclude that in this small randomized trial, FMT from a rationally selected donor was safe, associated with lower hospitalizations, and improved cognitive tests among patients with cirrhosis with recurrent HE.
